Cellectis
Yahoo Finance • 5 days ago
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading
European equities traded in the US as American depositary receipts were tracking lower late Thursday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 23 days ago
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges
On February 17, 2026, B Group, Inc. disclosed a new position in Structure Therapeutics(NASDAQ:GPCR), acquiring 90,000 shares in the fourth quarter. What happened B Group disclosed in a Securities and Exchange Commission (SEC) filing date... Full story
Yahoo Finance • 26 days ago
Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update
Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) ongoing Phase 1: 83% ORR at RP2D and 100% ORR in the target Phase 2 population In target Phase 2 population: 100% of patients became eligible to transplantPivotal Phase 2 first... Full story
Yahoo Finance • 26 days ago
Cellectis publie ses résultats financiers du quatrième trimestre 2025 et de l’exercice 2025 et une mise à jour de ses activités
Phase 2 pivot évaluant lasmé-cel dans la LAL-B en rechute ou réfractaire (étude BALLI-01) en cours Phase 1 : 83 % d’ORR à la dose RP2D et 100 % d’ORR dans la population cible de phase 2.Population cible de phase 2 : 100 % des patients son... Full story
Yahoo Finance • last month
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS, NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapi... Full story
Yahoo Finance • last month
Cellectis publiera ses résultats financiers du quatrième trimestre et de l’année 2025 le 19 mars 2026
NEW YORK, 12 mars 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du génome TALEN® pour développer des thérapies innov... Full story
Yahoo Finance • 2 months ago
European Equities Traded in the US as American Depositary Receipts Little Changed in Tuesday Trading
European equities traded in the US as American depositary receipts were little changed late Tuesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story
Yahoo Finance • 2 months ago
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
European equities traded in the US as American depositary receipts started the week modestly higher PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story
Yahoo Finance • 2 months ago
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Thursday Trading
European equities traded in the US as American depositary receipts were falling sharply late Thursda PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 4 months ago
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading
European equities traded in the US as American depositary receipts tracked lower late Tuesday mornin PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 4 months ago
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
Arbitration Ruling Reaffirms Allogene’s Full Control of Cemacabtagene Ansegedleucel (Cema-Cel)Decision Reconfirms Allogene’s Expanded Sub-License Covering EU and UK Rights with Options for Japan and China, Clearing the Path for Allogene to... Full story
Yahoo Finance • 4 months ago
ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL
Eti-cel showed an 88% ORR and 63% CR (n=8) at current dose level in r/r NHL after ≥2 prior lines of therapyIn vivo data suggest IL-2 may further enhance response rates and optimize eti-cel expansion and persistenceIL-2 cohort enrollment to... Full story
Yahoo Finance • 4 months ago
ASH 2025 : Cellectis présente son plan de développement pour renforcer les taux de réponse élevés obtenus avec éti-cel dans le LNH en rechute ou réfractaire
Éti-cel a montré un taux de réponse globale (ORR) de 88 % et un taux de réponse complète (CR) de 63 % (n=8) au niveau de dose actuel chez des patients atteints de LNH en rechute ou réfractaire après au moins deux lignes de traitement Des d... Full story
Yahoo Finance • 5 months ago
Cellectis organise un webinaire dédié aux actionnaires français le jeudi 4 décembre 2025
PARIS, 27 nov. 2025 (GLOBE NEWSWIRE) -- Cellectis (la « Société ») (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa plateforme pionnière d'édition de génome pour développer des thérapie... Full story
Yahoo Finance • 5 months ago
Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells
NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapi... Full story
Yahoo Finance • 5 months ago
Cellectis publie un article dans Nature Communications sur un procédé d’édition génomique non viral efficace pour l’insertion génique dans les cellules souches hématopoïétiques
NEW YORK, 19 nov. 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa plateforme pionnière d'édition de génome pour développer des thérapies cellulaires... Full story
Yahoo Finance • 5 months ago
Here are the major earnings after the close Thursday
Major earnings expected after the bell on Thursday include: * Applied Materials (AMAT [https://seekingalpha.com/symbol/AMAT]) * Virgin Galactic Holdings (SPCE [https://seekingalpha.com/symbol/SPCE]) * Nu Holdings Ltd. (NU [https://s... Full story
Yahoo Finance • 5 months ago
Cellectis Q3 2025 Earnings Preview
* Cellectis (CLLS [https://seekingalpha.com/symbol/CLLS]) is scheduled to announce Q3 earnings results on Thursday, November 13th, after market close. * The consensus EPS Estimate is -$0.11 [https://seekingalpha.com/symbol/CLLS/earning... Full story
Yahoo Finance • 5 months ago
After-Hours Biotech Watch: IFRX, ABCL, RLYB Among Notable Risers
(RTTNews) - Several biotechnology and pharmaceutical stocks showed notable price increases during Friday's after-hours trading session, with movement driven by upcoming data releases, recent earnings reports, and prior corporate updates.... Full story
Yahoo Finance • 5 months ago
Cellectis GAAP EPS of $0.01 beats by $0.24, revenue of $37.16M
* Cellectis press release [https://seekingalpha.com/pr/20299460-cellectis-reports-third-quarter-2025-financial-results-and-provides-business-update] (CLLS [https://seekingalpha.com/symbol/CLLS]): Q3 GAAP EPS of $0.01 beats by $0.24. *... Full story
